China SXT Pharmaceuticals, Inc. (SXTC) AI Stock Analysis

China SXT Pharmaceuticals, Inc. is a Taizhou, China-based pharmaceutical enterprise established in 2005. The company specializes in the development, manufacturing, and distribution of traditional Chinese medicine piece tablets (TCMP). Its product catalog features advanced, fine, and regular TCMP products including ChenXiang, SanQiFen, SuMu, and RenShen, marketed under brand names such as Suxuantang, Hui Chun Tang, and Tong Ren Tang. As of March 31, 2022, the company served 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals across 10 provinces and municipalities in China.

China SXT Pharmaceuticals experienced consistent revenue contraction over five years, with a 5-year revenue CAGR of -25.8% from FY2021 to FY2026. Annual revenue dropped from $2.6M in FY2022 to $1.1M in FY2026, falling 38.4% in FY2026 alone. Gross margin compressed from 48.1% in FY2022 to 17.1% in FY2026, while operating margin deteriorated to -664.1%. Net loss expanded to -$6.2M in FY2026, resulting in a net margin of -578.5%. For the latest quarter ended June 30, 2026, quarterly revenue declined 43.9% year-over-year, though quarterly earnings growth showed a 42.6% increase.

As of June 30, 2026, China SXT Pharmaceuticals held $28.2M in cash and short-term investments against total debt of $1.1M, yielding net cash of $27.1M. The company maintains a current ratio of 7.93 and a debt-to-equity ratio of 0.04, with shareholders' equity of $29.7M. In FY2026, operating cash flow stood at -$4.0M and free cash flow was -$4.0M, alongside capital expenditures of $4. Over a 5-year period, the company's share count increased by 1024.4%.

With a market capitalization of $673,237 and an enterprise value of -$23.7M, SXTC trades at a price-to-sales ratio of 0.6x, compared to 4.1x for the median of its US-listed Healthcare peers. Its EV-to-EBITDA ratio is 7.1x, below the peer group median of 12.0x, while its price-to-book ratio is 0.1x. The stock closed at $0.07 on October 16, 2026. SXTC delivered a 1-year return of -100.0%, lagging the S&P 500 benchmark return of 16.8%, and also returned -100.0% over 5 years versus 83.0% for the index.

Wall Street research coverage for China SXT Pharmaceuticals is limited, with no published consensus rating counts, analyst price targets, or forward earnings per share estimates available. Over the past four quarters, the company recorded 0 EPS beats against historical consensus benchmarks. In addition, no upcoming earnings release date is scheduled. Trading at a last close of $0.07 on October 16, 2026, the company currently operates without formal analyst guidance or target expectations.

This page is an AI-written research summary of China SXT Pharmaceuticals, Inc. (SXTC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SXTC income statement, SXTC balance sheet, SXTC key metrics, SXTC chart. See the SXTC stock overview for the latest quote and news.